Cytogenetic changes in patients with medulloblastoma and their prognostic value
In this study we revealed amplification of myc family genes and evaluated the status of chromosome 17 in medulloblastoma cells. Amplification of the myc gene family has been detected in 4 of 18 patients (22.2%), aberrations in 17 chromosome were detected in 7 out of 13 (58.3%). A negative correlation between the presence of family myc oncogene amplification with overall survival of patients has been detected. There was no relationship between changes on chromosome 17, and overall survival in patients with medulloblastoma. The presence of these aberrations is a predictor of poor response to therapy, and the high risk of relapse. This allows to carry out a more accurate stratification of patients into risk groups to determine the intensity and duration of therapy.